Conflict of interest: None declared.

References

Anti-inflammatory effects of targeted lung denervation in patients with COPD

To the Editor:

Acetylcholine is the primary parasympathetic neurotransmitter in the airways and induces bronchoconstriction via binding with M3 receptors. Cholinergic tone is increased in patients with chronic obstructive pulmonary disease (COPD) and this is the major reversible component of airflow obstruction in the disease [1]. Accordingly, treatment with anticholinergics is an effective bronchodilator therapy for patients with COPD [2]. Recent evidence from animal models of COPD revealed that acetylcholine also promotes airway inflammation and remodelling, which can be inhibited by anticholinergic intervention [3]. Such an anti-inflammatory effect of anticholinergic intervention could be clinically relevant. It has not been previously demonstrated in patients with COPD.

We investigated the effect of targeted lung denervation (TLD) on airway inflammation in COPD. TLD is a novel potential therapy for COPD, in which parasympathetic airway nerves are ablated by applying radiofrequency energy using a bronchoscopically guided catheter-based lung denervation system (Holaira, Inc., Plymouth, MN, USA) [4]. The lung denervation system includes a cooled electrode that is designed to generate therapeutic lesions at a sufficient depth from the inner surface of the main bronchus to ablate the airway nerves that travel parallel to and outside of the main bronchi and into the lungs. An expandable balloon provided protective cooling to minimise airway wall effects in the main bronchi during...
radiofrequency ablation of the nerves. Clinical evidence in COPD suggests that TLD improves lung function and quality of life [4]. We hypothesised that TLD would inhibit airway inflammation. Specifically, we studied whether TLD affects 1) inflammatory cell number and pro-inflammatory cytokine expression in bronchial wash fluid, and 2) gene expression of pro-inflammatory cytokines in bronchial brush specimens.

Patients with moderate-to-severe COPD were recruited as part of a safety and technical feasibility study for TLD (clinical trial number NCT01483534) [4]. Subjects recruited at the University Medical Center Groningen (Groningen, the Netherlands) (n=7, two males, age 56±10 years, smoking history 36±14 pack-years, forced expiratory volume in 1 s (FEV1) 27.6±6.7% predicted and 0.70±0.13 L, forced vital capacity (FVC) 2.19±0.27 L; all mean±sd, pre-bronchodilator FEV1 and FVC) were included in the sub-study investigating the effects of TLD on inflammation. Patients used oral corticosteroids during the interventions, and there was no additional use of anti-inflammatory medication. Patients were allowed to use their regular medication. TLD of the right lung was performed on day 0. A bronchial wash (two times 25 mL of saline) and brush were collected from the lung distal to the site of denervation before (day 0) and after denervation (day 30). On the bronchial wash, a differential cell count was performed on cytospin preparations stained for May–Grünewald and Giemsa (both from Sigma, St Louis, MO, USA) by counting 400 cells in duplicate in a blinded fashion. Cytokine concentrations in the wash were determined using a multiplex assay (26-plex; Millipore, Billerica, MA, USA). The following cytokines were measured: C-C chemokines CCL2, CCL4 and CCL11, C-X-C chemokines CXCL8 and CXCL10, granulocyte colony-stimulating factor (CSF), interferon (IFN)-α2, interleukin (IL)-6 and IL-7. The following cytokines were below the detection limit of 3.2 pg·mL$^{-1}$: granulocyte-macrophage CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, macrophage inflammatory protein (MIP)-1α, tumour necrosis factor (TNF)-α and TNF-β. From the bronchial brush, total RNA was extracted (Qiagen, Venlo, the Netherlands), reverse transcribed and subjected to quantitative reverse transcriptase PCR to analyse gene expression levels of CXCL8, IL-6, transforming growth factor (TGF)-β and mucin MUC5AC using 18S as a reference gene. Comparisons between day 0 and day 30 were performed using a Wilcoxon signed rank test and differences were considered statistically significant at p<0.05.

The results are presented in figure 1, where the relative change at day 30 compared with day 0 in levels of neutrophils and protein expression of CXCL8 (IL-8) and CCL4 (MIP-1β) in the bronchial wash, and the relative change in gene expression of CXCL8, IL-6, TGF-β and MUC5AC in the bronchial brush is depicted. For the seven patients studied, the percentage of neutrophils in the bronchial wash was decreased after TLD in five patients, CXCL8 decreased in four patients and CCL4 decreased in six patients (p=0.047). Gene expression of CXCL8 in the brush decreased in six patients (p=0.031), as did IL-6 in five patients, TGF-β in six patients (p=0.047) and MUC5AC in five patients. No significant change in the number of macrophages, lymphocytes, eosinophils and the additional cytokines was observed. In this small study population, a repeated measures ANCOVA did not show significant interactions of these parameters with changes in clinical parameters, including FEV1, in response to TLD.

Our findings suggest that TLD attenuates airway inflammation. Evidence from patients on the role of acetylcholine in inflammation is limited. Although the use of tiotropium bromide is associated with a
reduction in exacerbation frequency [2], methodological problems have hampered the evaluation of inflammation in the available drug study [5]. This bronchoscopic targeting of the parasympathetic system enabled us to examine the effects on airway inflammation in a completely novel, direct manner. Pre-clinical studies using sheep models have demonstrated effective destruction of cholinergic airway nerves by this device [6]. Although denervation also targets sensory nerve fibres that release pro-inflammatory neuropeptides, such as substance P and calcitonin gene-related peptide, these nerves have been shown to regenerate in the sheep model, in contrast to cholinergic nerve fibres. We cannot verify the impact of the TLD treatment on individual nerve fibres and mediators in the patients in the current study; therefore, it is important to stress that whereas we believe that these findings suggest a pro-inflammatory role for acetylcholine in the airways, the involvement of additional neurotransmitters and neuropeptides cannot be excluded. In addition, there might be subtle changes in bronchial vessels that could contribute to leukocyte supply, although TLD in sheep did not result in a discernible change in bronchial vessel number or calibre distal to the treatment site. Therefore, we propose that this anti-inflammatory effect of TLD is mediated via inhibition of acetylcholine release.

A pro-inflammatory role for acetylcholine has already been proposed from animal models of COPD [3]. It has been shown that lipopolysaccharide-induced and cigarette smoke-induced inflammation and remodelling can be inhibited by anticholinergic treatment or by knock-out of the muscarinic M3 receptor [7, 8].

Acetylcholine is not only a neurotransmitter but is also produced by non-neuronal cells. It has been proposed that this non-neuronal acetylcholine is responsible for the pro-inflammatory effects of acetylcholine [9, 10]. The current study suggests that neuronal acetylcholine may in fact contribute to inflammation in COPD.

Furthermore, TLD might also have effects on airway remodelling, since a significant reduction in TGF-β was observed. This aligns well with the reduction in TGF-β we have previously found in muscarinic M3 receptor knock-out mice [8], and with the human data from the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, where tiotropium reduced lung function decline in a subgroup of patients [11].

There are limitations to this small cohort pilot study, including the limited number of subjects and the lack of control of successful denervation. However, we believe that the findings are promising, and a large-scale multicentre sham-controlled study of the effectiveness of TLD is planned and will include similar analyses. This should provide more evidence for the role of neuronal acetylcholine as a pro-inflammatory mediator. Moreover, it would be interesting to perform similar analyses in patients treated with anticholinergic drugs. Whether anticholinergic intervention will become a tool to treat inflammation is a question to be confirmed in the future.

In conclusion, our findings constitute explorative evidence for a role of TLD in inhibition of inflammation in patients with COPD. This is of clinical interest because current anti-inflammatory therapy, including corticosteroids, is of limited effectiveness. This is a novel and sparsely explored intervention that might affect treatment strategy in COPD in the future.

References
Combined comorbidity was defined by the presence of chart-based and/or objectively identified comorbidity as atherosclerosis. Chart-based and objective assessments were independently recorded and assessed. Depression; and platelet aggregation inhibitors (used only for secondary prophylaxis in the Netherlands) [13]

Drugs as dyslipidaemia; bisphosphonates as osteoporosis; anxiolytics or sedatives as anxiety; antidepressants as

Comorbidities were identified objectively, based on predefined cut-offs: chronic kidney disease (estimated glomerular filtration rate <60 mL·min−1 (Cockroft–Gault formula)) [3]; anaemia (haemoglobin <8.1 mmol·L−1 in men or <7.5 mmol·L−1 in women) [4]; hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) [5]; low muscle mass (fat-free mass index <16 kg·m−2 for men or <15 kg·m−2 for women) [6]; diabetes mellitus (fasting plasma glucose ≥7.0 mmol·L−1) [7]; dyslipidaemia (low-density lipoprotein (LDL)–cholesterol ≥2.5 mmol·L−1 [8]; osteoporosis (t-score < −2.5) [9]; symptoms of anxiety and depression (Hospital Anxiety and Depression Scale (HADS) score ≥10) [10]; atherosclerosis (carotid intima–media thickness >0.9 mm) [5]; and myocardial infarction (cardiac infarction injury score ≥20) [11]. The technical details of these assessments have been published previously [12].

Chart-based comorbidities were assessed by combining the medical history recorded in the chest physician’s referral letter, the patient’s interview and an overview of current pharmacological therapy provided by the patient’s pharmacist. Chart-based atherosclerosis was defined as ischaemic cerebrovascular disease, coronary artery disease, peripheral arterial disease and/or aortic aneurysms. Concerning pharmacotherapy, the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, β-blockers or diuretics was labelled as hypertension; oral antidiabetics or insulin as diabetes mellitus; lipid-lowering drugs as dyslipidaemia; bisphosphonates as osteoporosis; anxiolytics or sedatives as anxiety; antidepressants as depression; and platelet aggregation inhibitors (used only for secondary prophylaxis in the Netherlands) [13] as atherosclerosis. Chart-based and objective assessments were independently recorded and assessed. Combined comorbidity was defined by the presence of chart-based and/or objectively identified comorbidity

To the Editor:

Comorbidities contribute significantly to the individual burden of disease in patients with chronic obstructive pulmonary disease (COPD). Their assessment is considered essential for COPD management and is frequently based on data from patients’ charts [1]. However, comorbidities are often undiagnosed [2]. Hence, a mismatch between chart-based and objectively identified comorbidities could be anticipated.

The current cross-sectional analyses were based on data collected in the Centre of Expertise for Chronic Organ Failure (CIRO) Comorbidity study (Maastricht University Medical Centre ethics committee approval number 10-3-067). 11 clinically relevant chart-based and objectively identified comorbidities were assessed in a cohort of patients with clinically stable COPD referred for pulmonary rehabilitation. Patients with a history of asthma, α1-antitrypsin deficiency, any previous lung surgery, active inflammatory disease, acute myocardial infarction within the last 6 months, any known bone disease other than osteoporosis, current or recently (i.e. 5 years before the study) treated malignant disease, or use of high-dose systemic glucocorticosteroids (>10 mg prednisolone) were excluded.

Comorbidities were identified objectively, based on predefined cut-offs: chronic kidney disease (estimated glomerular filtration rate <60 mL·min−1 (Cockroft–Gault formula)) [3]; anaemia (haemoglobin <8.1 mmol·L−1 in men or <7.5 mmol·L−1 in women) [4]; hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) [5]; low muscle mass (fat-free mass index <16 kg·m−2 for men or <15 kg·m−2 for women) [6]; diabetes mellitus (fasting plasma glucose ≥7.0 mmol·L−1) [7]; dyslipidaemia (low-density lipoprotein (LDL)–cholesterol ≥2.5 mmol·L−1 [8]; osteoporosis (t-score < −2.5) [9]; symptoms of anxiety and depression (Hospital Anxiety and Depression Scale (HADS) score ≥10) [10]; atherosclerosis (carotid intima–media thickness >0.9 mm) [5]; and myocardial infarction (cardiac infarction injury score ≥20) [11]. The technical details of these assessments have been published previously [12].

Chart-based comorbidities were assessed by combining the medical history recorded in the chest physician’s referral letter, the patient’s interview and an overview of current pharmacological therapy provided by the patient’s pharmacist. Chart-based atherosclerosis was defined as ischaemic cerebrovascular disease, coronary artery disease, peripheral arterial disease and/or aortic aneurysms. Concerning pharmacotherapy, the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, β-blockers or diuretics was labelled as hypertension; oral antidiabetics or insulin as diabetes mellitus; lipid-lowering drugs as dyslipidaemia; bisphosphonates as osteoporosis; anxiolytics or sedatives as anxiety; antidepressants as depression; and platelet aggregation inhibitors (used only for secondary prophylaxis in the Netherlands) [13] as atherosclerosis. Chart-based and objective assessments were independently recorded and assessed. Combined comorbidity was defined by the presence of chart-based and/or objectively identified comorbidity